Want to see INBX full AI Analyst Report?
Total Valuation
Inhibrx Biosciences Inc has a market cap or net worth of $1.61B. The enterprise value is $1.53K.
Market Cap$1.61B
Enterprise Value$1.53K
Share Statistics
Inhibrx Biosciences Inc has 14,717,660 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding14,717,660
Owned by Insiders16.15%
Owned by Institutions44.02%
Financial Efficiency
Inhibrx Biosciences Inc’s return on equity (ROE) is -17.52 and return on invested capital (ROIC) is -117.41%.
Return on Equity (ROE)-17.52
Return on Assets (ROA)-0.96
Return on Invested Capital (ROIC)-117.41%
Return on Capital Employed (ROCE)-1.20
Revenue Per Employee11.82K
Profits Per Employee-1.27M
Employee Count110
Asset Turnover<0.01
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Inhibrx Biosciences Inc is ―. Inhibrx Biosciences Inc’s PEG ratio is 0.08.
PE Ratio―
PS Ratio941.13
PB Ratio153.07
Price to Fair Value153.07
Price to FCF-9.42
Price to Operating Cash Flow-12.99
PEG Ratio0.08
Income Statement
In the last 12 months, Inhibrx Biosciences Inc had revenue of 1.30M and earned -140.06M in profits. Earnings per share was -9.04.
Revenue1.30M
Gross Profit-1.18M
Operating Income-135.03M
Pretax Income-140.05M
Net Income-140.06M
EBITDA-125.37M
Earnings Per Share (EPS)-9.04
Cash Flow
In the last 12 months, operating cash flow was -131.89M and capital expenditures 17.00K, giving a free cash flow of -131.87M billion.
Operating Cash Flow-131.89M
Free Cash Flow-131.87M
Free Cash Flow per Share-8.96
Dividends & Yields
Inhibrx Biosciences Inc pays an annual dividend of $0.85, resulting in a dividend yield of 5.23%
Dividend Per Share$0.85
Dividend Yield5.23%
Payout Ratio―
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.34
52-Week Price Change303.21%
50-Day Moving Average99.26
200-Day Moving Average90.18
Relative Strength Index (RSI)51.37
Average Volume (3m)335.88K
Important Dates
Inhibrx Biosciences Inc upcoming earnings date is Nov 13, 2026, After Close (Confirmed).
Last Earnings DateAug 13, 2026
Next Earnings DateNov 13, 2026
Ex-Dividend Date―
Financial Position
Inhibrx Biosciences Inc as a current ratio of 3.93, with Debt / Equity ratio of -10.08%
Current Ratio3.93
Quick Ratio3.93
Debt to Market Cap0.08
Net Debt to EBITDA0.14
Interest Coverage Ratio-11.07
Taxes
In the past 12 months, Inhibrx Biosciences Inc has paid 2.00K in taxes.
Income Tax2.00K
Effective Tax Rate>-0.01
Enterprise Valuation
Inhibrx Biosciences Inc EV to EBITDA ratio is -9.62, with an EV/FCF ratio of -9.29.
EV to Sales927.90
EV to EBITDA-9.62
EV to Free Cash Flow-9.29
EV to Operating Cash Flow-9.29
Balance Sheet
Inhibrx Biosciences Inc has $133.34M in cash and marketable securities with $5.34M in debt, giving a net cash position of $128.00M billion.
Cash & Marketable Securities$133.34M
Total Debt$5.34M
Net Cash$128.00M
Net Cash Per Share$8.70
Tangible Book Value Per Share$0.52
Margins
Gross margin is 0.00%, with operating margin of -10386.54%, and net profit margin of -10773.46%.
Gross Margin0.00%
Operating Margin-10386.54%
Pretax Margin-10773.31%
Net Profit Margin-10773.46%
EBITDA Margin-9644.15%
EBIT Margin-9835.15%
Analyst Forecast
The average price target for Inhibrx Biosciences Inc is $266.67, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$266.67
Price Target Upside117.30% Upside
Analyst ConsensusStrong Buy
Analyst Count3
Revenue Growth Forecast-100.00%
EPS Growth Forecast19.23%